Reference : Failure of Buserelin-Induced Medical Castration to Control Pulmonary Lymphangiomyomat...
Scientific journals : Article
Human health sciences : Surgery
Human health sciences : Cardiovascular & respiratory systems
Failure of Buserelin-Induced Medical Castration to Control Pulmonary Lymphangiomyomatosis in Two Patients
RADERMECKER, Marc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie cardio-vasculaire >]
Broux, R. []
Corhay, Jean-Louis mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
Limet, Raymond mailto [Université de Liège - ULiège > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique]
Radermecker, Maurice mailto [Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine) >]
American College of Chest Physicians
Yes (verified by ORBi)
[en] Two women, aged 44 and 29 years, respectively, were admitted to the hospital in early 1987 for recurrent pneumothorax, dyspnea and a diffuse reticulonodular pattern evidenced on the chest x-ray film. Lung biopsy confirmed LAM in both patients. Both were treated sequentially with medroxyprogesterone and a LHRH agonist (buserelin) to achieve reversible medical castration. Neither subjective nor objective improvement was noted after 13 and 5 months, respectively, of buserelin therapy (900 micrograms/day, nasal spray) despite an effective suppression of the pituitary-gonadal axis. Medroxyprogesterone also was ineffective. Buserelin thus failed to control pulmonary LAM in these two patients, in spite of effective medical castration.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Restricted access
RADERMECKER_CHEST_1992_101_1724.pdfPublisher postprint422.5 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.